Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 3/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624847 | 0.86 | APP (0.38) | PTPN1APPBACE1ALOX5 | |
| SCHEMBL2624846 | 0.86 | APP (0.38) | PTPN1APPBACE1ALOX5 | |
| SCHEMBL2624816 | 0.86 | ALOX5 (0.33) | APPALOX5 | |
| SCHEMBL2624862 | 0.86 | APP (0.38) | PTPN1APPBACE1ALOX5 | |
| SCHEMBL30678564 | 0.86 | APP (0.38) | PTPN1APPBACE1ALOX5 | |
| SCHEMBL16406486 | 0.83 | DHODH (0.45) | PTPN2PTPN1PTPN6DHODHAPP | |
| SCHEMBL29425569 | 0.82 | PTPN2 (0.40) | PTPN2PTPN1PTPN6DHODHAPP | |
| SCHEMBL9880209 | 0.82 | PTPN2 (0.40) | PTPN2PTPN1PTPN6DHODHAPP | |
| SCHEMBL22863342 | 0.79 | PTPN2 (0.38) | PTPN2PTPN1PTPN6DHODHAPP | |
| SCHEMBL22863341 | 0.79 | PTPN2 (0.38) | PTPN2PTPN1PTPN6DHODHAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | SHOWA UNIVERSITY (JP) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | PTPN2 2545/4885PTPN1 2665/4885PTPN6 1905/4885 |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | REN, ATP6V1B1, SLC10A1 | PTPN2 2956/4885PTPN1 3029/4885PTPN6 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.